Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Summit Therapeutics

Executive pay climbed again in 2025—and the CEO-to-worker gap kept widening

The gap between CEO and worker pay hit a four-year high in 2025, with median CEO compensation rising 13% to $4.75 million, per new data.

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market

Every market cycle has its own cast of optimists and skeptics. But few voices carry as much weight as the executives who actually run the companies we own. When those leaders open their own checkbooks for seven figure insider purchases, they are not talking, they are betting real money that…

What's Going On With Summit Therapeutics Stock On Monday?

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence

Picture this: It’s a Tuesday morning, and somewhere in America, a company’s CFO logs into their brokerage account and does something that would make most people’s palms sweat. They wire $1 million of their own money to buy shares of their company’s stock. Not stock options granted as part of…

Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended ringing the register on Opendoor Technologies Inc. (NASDAQ:OPEN). “We don't want to be in a meme stock,” he added.

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?

Summit Therapeutics is a clinical-stage biotech company that has returned over 1,100% in 2024. Is the stock still a good buy right now?

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks Finish Higher on Support From Chip Stock Rebound

Stocks Finish Higher on Support From Chip Stock Rebound

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. Stocks on Monday posted moderate gains on some dip buying following last Friday’s sharp...

Stocks Climb on Strength in Chip Stocks

Stocks Climb on Strength in Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.58%. Stocks today are moderately higher, recovering some of last Friday’s sharp sell-off on some...

5 Top-Rated Russell 2000 Stocks Crushing the Market in 2024

5 Top-Rated Russell 2000 Stocks Crushing the Market in 2024

With the Russell 2000 index taking a dip in 2024, these five top-rated RUT stocks are outshining their parent index and the broader market.

Chart of the Day: Summit Therapeutics Begins to Soar

Chart of the Day: Summit Therapeutics Begins to Soar

Caution: This company has had legal issues in the past. It is highly speculative. The Chart of the Day belongs to the oncology company Summit Therapeutics (SMMT) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha,...

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Palantir Technologies

Dell Technologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

397,436 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play